Multiple biomarkers have been established to predict or diagnose CRCLM, such as carcinoembryonic antigens in the serum,[50] CTCs,[51] and circulating tumor DNA (ctDNA).[52] However, these methods do not fully meet the requirements for the diagnosis of CRC metastasis at an early stage. This evidence concerns the gene CEACAM5 and neoplasm.